In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group has ...

The Food and Drug Administration has declared an end to the shortage of Novo Nordisk’s blockbuster ... sold under the brand names Ozempic for diabetes and Wegovy for obesity, had been on the ...

Shares of Novo Nordisk slipped in Monday morning trading ... trial to see how the drug compared to the company's other drugs, Ozempic, which is approved by the FDA for diabetes, and Wegovy ...

Novo Nordisk’s semaglutide weight-loss (Wegovy) and diabetes (Ozempic) drugs are no longer in short supply, U.S. regulators said Feb. 21, 2025, a decision that’s expected to curtail widespread ...

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will ... recently confirming that both Wegovy and Ozempic, forms of the GLP-1 medication semaglutide, are no longer in shortage.

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...